Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BiPar Sciences logo — Innovative therapies harnessing the power of PARP inhibitors...

BiPar Sciences

Innovative therapies harnessing the power of PARP inhibitors to combat advanced cancers

Founded 2002 Series C Total: $74.97M Biotechnology, Health Care +1

General Information

Company Name BiPar Sciences
Founded Year 2002
Founders / Decision Makers
Team member Team member
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series C
Social

Get notified when BiPar Sciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BiPar Sciences

BiPar Sciences, based in Brisbane, CA, is a biotechnology company focused on developing innovative therapies utilizing PARP inhibitors to combat advanced cancers. The company's leading experimental drug, BSI-201, is currently undergoing mid-phase trials aimed at treating advanced breast cancer, ovarian cancer, and other tumors. The company has attracted significant attention and support from notable venture capital firms, securing approximately $60 million in funding from investors including Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. Additionally, it has obtained venture debt from Lighthouse Capital Partners. In a significant development, on April 15, 2009, French pharmaceutical company Sanofi-Aventis S.A. announced its acquisition of BiPar Sciences in a deal valued at up to $500 million. Overall, BiPar Sciences has successfully positioned itself as a promising player in the biotechnology and pharmaceutical industries, garnering substantial investor backing and ultimately culminating in a noteworthy acquisition, signaling a successful exit for its backers.

Taxonomy: BiPar Sciences, PARP inhibitors, cancer therapies, BSI-201, oncology, venture capital, acquisition, Sanofi-Aventis, clinical trials, breast cancer, ovarian cancer, tumor treatment, drug development, pharmaceutical industry

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		12 Jan 2009
Series B •••••• 2
Investor
•••• •••• 		16 Apr 2008
Series A •••••• 1
Investor
01 Jan 2008
Series B •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		26 Feb 2007
Debt Financing •••••• 1 •••• •••• 14 Jun 2006

View All 8 Funding Rounds

BiPar Sciences Alternatives & Competitors

BiPar Sciences vs
Thrive Earlier Detection
Thrive Earlier Detection

Pioneering Life-Saving Cancer Detection with Advanced Liquid Biopsy Solutions

Series Unknown
Biotechnology, Health Care
BiPar Sciences vs
Nouscom
Nouscom Switzerland

Series C
57 employees
Biotechnology, Health Care
BiPar Sciences vs
Oxford Cancer Biomarkers
Oxford Cancer Biomarkers

Pioneering Precision Medicine

Grant
7 employees
Biopharma, Biotechnology

FAQ About BiPar Sciences

Innovative therapies harnessing the power of PARP inhibitors to combat advanced cancers
BiPar Sciences was founded in 2002.
BiPar Sciences operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
BiPar Sciences has completed 8 funding rounds, raising a total of $74.97M. The latest funding stage is Series C.
Top alternatives and competitors to BiPar Sciences include Thrive Earlier Detection, Nouscom , Oxford Cancer Biomarkers, Proacta, Amaroq Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BiPar Sciences and Thrive Earlier Detection are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BiPar Sciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy